Fragment Based Drug Discovery on Pioneer Systems Using Next Generation SPR Analysis
Fragment-based drug design (FBDD) has become an increasingly popular platform for the identification of lead candidates in drug discovery programs, with surface plasmon resonance (SPR) becoming a core technology in many pharma and biotech settings for the identification of low-affinity fragment compounds.
ForteBio has recently introduced the next generation in SPR biosensor analysis for fragments, exclusively available on Pioneer systems. This Next Generation SPR consists of OneStep® and NeXtStep™ gradient injection technologies.
Download this application note to learn about ForteBio's Next Generation SPR, including:
Fragment screening with OneStep and NeXtStep Injection techniques
Comparison of OneStep and conventional SPR in FBDD
